In this episode, I discuss corneal disease and treatments with David Eveleth, PhD, the founder, president and CEO of Trefoil Therapeutics.

Brought to you by Alcon

·       Welcome to another exciting episode of Eye Care insider :14

·       Intro David Eveleth, PhD :47

·       Eveleth’s background 1:05

·       What’s the treatment landscape now for corneal diseases and where are we falling short for patients? 2:59

·       The origins of Trefoil Therapeutics 7:27

·       FGF-1: Is it just important in the endothelium or is it also important in the epithelium? 11:47

·       What is your current lead investigational candidate? 14:01

·       When do you expect another read out of clinical data? 21:47

·       An adjunctive therapy with cataract surgery 18:27

·       What is the timeline of administration to patients? 19:24

·       When do you expect a readout of clinical data? 20:49

·       Is it possible to use this also for the epithelium? 21:39

·       What are the most important challenges facing the ophthalmic industry? What is the most important factor to look for? 24:07

·       For more information about David Eveleth, PhD, and Trefoil Therapeutics, visit www.trefoiltherapeutics.com 25:53

·       Corneal disease can be fixed and better vision is possible 26:44

·       Thanks for listening 27:04

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. You can find follow Trefoil Therapeutics on Twitter @TrefoilThera.

David Eveleth, PhD, is the president and CEO of Trefoil Therapeutics.

Disclosures: Eveleth is the founder, CEO and shareholder of Trefoil Therapeutics. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

In this episode, I chat with Nancy Lurker, CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials.

Brought to you by Alcon

·       Welcome to another exciting episode of Eye Care insider :13

·       Intro Nancy Lurker :22

·       Lurker’s background :58

·       EyePoint Pharmaceuticals: the origin and transition 2:29

·       Yutiq and long-acting drug delivery systems 6:07

·       Additional indications for Yutiq 8:30

·       What is the key factor in delivering this longer durability? 16:13

·       Any consideration of looking at superiority of visual acuity and anatomical OCT gains? 21:47

·       Is the primary focus wet AMD? Or are you also looking at NPDR and DME as potential indications? 24:19

·       Investor information and neural protection data 29:01

·       What is the most important issue that the field of ophthalmology is currently facing? 30:38

·       Thanks for listening 32:37

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. You can find Nancy Lurker at @EyePointCEO and @EyePointPharma.

Nancy Lurker is the board director and CEO of EyePoint Pharmaceuticals.

Disclosures: Lurker is the board director and CEO of EyePoint Pharmaceuticals. Mali reports he is founder and CEO of Mali Enterprises; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

In this episode, I discuss Samsara Vision’s SING IMT and its benefits of vision improvement for patients with AMD with Rebecca Kammer, OD, PhD.

Brought to you by Alcon

·       Welcome to another exciting episode of Eye Care insider :14

·       Intro for Rebecca Kammer, OD, PhD :27

·       Dr. Kammer’s background 1:28

·       Defining late-stage AMD patients and treatments available 5:11

·       The SING IMT 9:46

·       US Concerto Study Website – to learn more about the study 13:13

·       Visual acuity and the SING IMT 13:48

·       US trial, recruitment and patient eligibility 17:18

·       Contact toll-free 1-866-393-3767 discuss eligibility, participation and questions 20:39

·       SING IMT as an option for patients 22:55

·       Thanks for listening 27:30

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. You can reach Dr. Kammer at [email protected].

Rebecca Kammer, OD, PhD, is the vice president of worldwide clinical and medical affairs for Samsara Vision, Inc., an adjunct professor at University of California, Irvine and a diplomate in low vision of the American Academy of Optometry.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI. Kammer reports being a clinical advisor to Biovisics and Eyedaptic.

In this episode, I share my top five predictions for 2023 in the field of ophthalmology.

Brought to you by Alcon

• Welcome to another exciting episode of Eye Care insider :52
• My review of the top five predictions in ophthalmology 1:03
• Prediction #1 – Vabysmo and anti-VEGF market 1:53
• Prediction #2 – FDA approval for GA treatment 4:26
• Prediction #3 – SNAPS eye shield for ocular protection 6:06
• Prediction #4 – biosimilars and the ophthalmic therapeutic marketplace 10:08
• Prediction #5 – retina analytical tools 12:27
• Thanks for listening 14:30

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI.

In this episode, I share my thoughts about the five greatest innovations of the 21st century in the field of ophthalmology and how they have changed patient outcomes for the better.

Brought to you by Alcon

• Welcome to another exciting episode of Eye Care insider :50
• My review of the top five innovations in ophthalmology 1:02
• Greatest Innovation #1 – anti-VEGF medications 2:06
• Greatest Innovation #2 – intraocular lens implantation technology 3:26
• Greatest Innovation #3 – electronic medical records 4:08
• Greatest Innovation #4 – optical coherence tomography 5:48
• Greatest Innovation #5 – telemedicine 6:35
• Thanks for listening 7:44

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular  Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, I share my review of the hot topics from the AAO 2022 annual meeting and share my thoughts on the new data shared about drug trials and treatments.

Brought to you by Alcon

• Welcome to another exciting episode of Eye Care insider :53
• My review of the hot topics from the AAO 2022 annual meeting 2:20
• Hot Topic #1 – wet AMD treatments 2:40
• Hot Topic #2 – high-dose Eylea 6:20
• Hot Topic #3 – geographic atrophy treatments 10:24
• Thanks for listening 16:04

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, I share my preview of the hot topics for the upcoming AAO 2022 annual meeting, including my thoughts on ocular gene therapy and new treatments in the works.

• Welcome to another exciting episode of Eye Care insider :52
• My preview of hot topics for the upcoming AAO 2022 annual meeting 1:04
• Hot Topic #1 – new treatments for dry AMD or geographic atrophy 2:43
• Hot Topic #2 – wet AMD management 5:55
• Hot Topic #3 – ocular gene therapy 7:56
• Hot Topic #4 – biosimilars 9:17
• Thanks for listening 11:22

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.

In this episode, Jose O. Segura, wealth management advisor and certified business exit planner, discusses establishing objectives within financial planning and organization, how to diversify your portfolio in ever-changing markets and more.

• Intro :38
• Welcome to another episode of Eye Care insider :52
• About Jose Segura 1:03
• For people that are listening for the first time, do you mind giving a brief of your background? 1:32
• What are, in your opinion, some best practices in regard to financial planning? 2:58
• Process for financial organization and seeking out advisors. 10:09
• Can you talk about the importance of portfolio diversification? 12:07
• Importance of maintaining your overall focus on financial planning and strategies when markets are effected. 16:56
• Could you give us one pearl for our listeners, or one key economic update that you think would be really important to the current economic situation right now? 18:49
• Thank you Jose 23:09
• Any final words to our listeners? 23:11
• Outro 23:35

Jose O. Segura, is a wealth management advisor and certified business exit planner.

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. For more information about Segura, visit www.joseosegura.com, reach him by email at [email protected], or call 518-867-3210 x104.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Segura reports he is a registered Representative and Financial Advisor of Park Avenue Securities LLC (PAS), 355 Lexington Avenue, 9 Fl., New York, NY 10017, 212-541-8800.

In this episode, Ashlie Leal, director of ophthalmology at FundamentalVR, discusses their fully immersive surgical training products, how virtual reality plays a role in training surgeons and more.

• Intro :38
• Welcome to another episode of Eye Care insider :52
• About Ashlie Leal 1:00
• Give me a little bit of your background – how you got into this industry and your role at FundamentalVR? 1:33
• Can you give our listeners some background about FundamentalVR as a company, and why should eye care professionals start paying attention to your company? 2:56
• Do you target training programs? … Is there a certain focus to your company in regards to demographics? 4:12
• Is there any way you can describe [your virtual reality products] or any current product offers that you have that apply to eye care professionals? 7:30
• You’re using a headset and the two arms. Is that all you would need, or would you need some sort of base mannequin head with an eyeball simulation? 9:25
• You can do it anywhere, theoretically? And you can simulate different MIGS equipment and different ocular lens implants based on the tech simulating that equipment? 10:59
• So, the simulation is able to carry out these multiple, intricate steps? 12:03
• Is there current gene therapy that is utilizing your technology? Do you have a relationship with them in the sense that you provide the surgeons with the virtual reality simulations? 12:49
• Do you have any sort of data or any procedure done with virtual reality improving complication rate and efficiency? 14:02
• What does the future look like for virtual reality? What would you say is the major challenge, or what does your company hope to accomplish in the next few years or the decade? 15:30
• What’s that process look like for a company to approach you for virtual reality offering to train on a new device? How long does that process take, and what are the steps to assimilate their product into your technology? 17:14
• If someone wants to learn more, how can they contact you or your company for more information? 19:13
• Congratulations Ashlie and FundamentalVR 19:39
• Any final words to our listeners? 20:02
• Outro 20:39

Ashlie Leal is director of ophthalmology, FundamentalVR.

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. Leal can be reached on LinkedIn or at www.fundamentalsurgery.com.   

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Leal reports she is director of ophthalmology at FundamentalVR.

In this episode, Allisa Song, a medical student and the CEO and co-founder of Nanodropper, discusses the inception of the device, how it can benefit the eye care industry and more.

• Intro :38
• Welcome to another episode of Eye Care insider :52
• About Allisa Song 1:01
• I want to hear your story about the history about the Nanodropper – how you came to this idea; what problem you were trying to solve; and how you got here? 2:02
• What are the major advantages of your product? Why doesn’t our standard bottle function properly like that? 5:06
• Can this go on every eyedrop bottle? 6:49
• Is there any sort of data that we can look at that shows how much volume of the prescription is saved? 7:51
• Can you talk to me about how industry has taken this? What is your take on how they feel about your product? 12:15
• How are you distributing your product to the consumers and to the masses? What are your channels to get the product out there? 15:36
• What do you think the future holds for Nanodropper? Where do you see this going in the next 3 to 5 years? 17:04
• Is there any information that you can provide to our listeners can go to and learn more about your story? 18:23
• Congratulations again Allisa 19:03
• You’ll be graduating from medical school pretty soon? 19:15
• Any final words to our listeners? 19:50
• Outro 20:26

Allisa Song, is a Mayo Clinic Alix School of Medicine medical student and the CEO and co-founder of Nanodropper. Song is a serial entrepreneur and inventor with a background in Clean Tech, neuroscience, and harm reduction. In addition to her proven track record of successful fundraising, she has led her teams to dozens of business and design awards, including her most recent USPTO Collegiate Inventor medal awarded by the National Inventors Hall of Fame. 

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. Song can be reached at [email protected].  

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Song is the CEO and co-founder of Nanodropper and serves as an advisor for Bedo Solutions.

In this episode, Arthur Benjamin, MD, discusses dry eye treatment and trends, the challenges dry eye patients and the eye care professionals treating them and more.

• Intro :37
• Welcome to another episode of Eye Care insider :51
• About Arthur Benjamin, MD 1:02
• I wonder if you could talk about your training and what you currently do now? 1:39
• Could you talk about what you’ve seen throughout the years and what you’ve seen in the trends in dry eye and how it has expanded in the population? 2:56
• What is your current algorithm for someone with dry eye? How do you manage that? 5:01
• Once you do determine they have moderate dry eye where do you start with the patient or the treatment paradigm? 7:00
• With the OptiLight treatment option … what do you tell patients? What should they be expecting? 9:54
• I recently saw that there’s been a campaign from OptiLight involving Mandy Moore. Could you talk about that campaign and discuss it a little bit further? 12:54
• What do you think is the most important topic or issue or challenge that are facing dry eye patients today or eye care professionals treating patients with dry eye? 16:07
• What a fascinating discussion 17:43
• Any last words? 17:55
• Outro 18:09

Arthur Benjamin, MD, is a clinical assistant professor at the Jules Stein/Doheny Eye Institute at UCLA’s Geffen School of Medicine and is in private practice at Benjamin Eye Institute.  

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. Dr. Benjamin can be contacted by going to BenjaminEye.com.

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Benjamin reports no relevant financial disclosures.